XM does not provide services to residents of the United States of America.
T
T

ThermoFisher

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Gene therapy maker bluebird to revise financials after accounting errors

UPDATE 3-Gene therapy maker bluebird to revise financials after accounting errors Adds company statement in paragraph 3, updates shares March 26 (Reuters) - Gene therapy maker bluebird bio BLUE.O said on Tuesday it plans to revise its financial statements for 2022 and the first three quarters of last year due to accounting errors related to some contract manufacturing agreements.
L
T

U.S. Lennar, Republic Services, Ulta Beauty

U.S. RESEARCH ROUNDUP-Lennar, Republic Services, Ulta Beauty March 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Lennar, Republic Services and Ulta Beauty, on Monday. HIGHLIGHTS * Adobe Inc ADBE.O : Citigroup cuts target price to $554 from $628 * Lennar Corp LEN.N : JP Morgan cuts target price to $157 from $161 * Republic Services Inc RSG.N : Jefferies raises target price to $225 from $213 * Ulta Beauty Inc ULTA.
A
C
F
G
N
T
W
U
E
T
H
I
R

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

BRIEF-Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink March 1 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXTENDS THE EXPIRATION OF TENDER OFFER FOR ALL OUTSTANDING COMMON SHARES AND ADSS OF OLINK THERMO FISHER SCIENTIFIC INC - OFFER NOW SCHEDULED TO E
T

Agilent reports better-than-expected first quarter results, shares rise

Agilent reports better-than-expected first quarter results, shares rise Feb 27 (Reuters) - Agilent Technologies A.N on Tuesday beat Wall Street estimates for first-quarter profit and revenue, helped by strong sales in its life sciences and diagnostics units, sending shares up 5% in extended trading. The equipment maker reported quarterly revenue of $1.66 billion, which was above analysts' estimates of $1.58 billion, according to LSEG data.
A
T

IQVIA quarterly results beat estimates on strong demand for research services

IQVIA quarterly results beat estimates on strong demand for research services Feb 14 (Reuters) - IQVIA Holdings IQV.N beat Wall Street estimates for fourth-quarter sales and profit on Wednesday, on the back of strong demand for its drug research and development services. Shares of IQVIA were up nearly 5% before the bell. IQVIA's quarterly results provide some relief about concerns of sluggish demand for contract research services as rising interest rates squeeze funding this year, prompting biot
T
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.